T. Rowe Price Investment Management, Inc. Arcellx, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,665,138 shares of ACLX stock, worth $108 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,665,138
Previous 705,922
135.88%
Holding current value
$108 Million
Previous $54.1 Million
101.77%
% of portfolio
0.07%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding ACLX
# of Institutions
214Shares Held
48.8MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$293 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$260 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$244 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$229 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$198 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.85B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...